Stephen M. Kaminsky   Professor of Research in Genetic Medicine

Phone
  • +1 646 962 5744

Publications

Sort by

selected publications

Research

Sort by

Funding awarded

  • missing activity Principal Investigator 2020 - 2024
  • Gene Therapy for Alpha 1-Antitrypsin Deficiency  awarded by National Heart, Lung, & Blood Institute Co-Investigator 2024 - 2025
  • Rapid Noninvasive Whole-body Imaging of AAV Gene Transfer Vectors  awarded by National Institute of Biomedical Imaging & Bioengineering Co-Investigator 2019 - 2025
  • Manufacturing Services Agreement between PTC and WCM  awarded by PTC Therapeutics Co-Investigator 2019 - 2024
  • missing activity Co-Investigator 2019 - 2024
  • Phase IA/IB Study of AAVrh.10hFXN Therapy to Treat the Cardiomyopathy of Friedreich''s Ataxia  awarded by National Heart, Lung, & Blood Institute Co-Principal Investigator 2020 - 2025

Teaching

teaching overview

  • Lecturer: MOLECULAR BIOLOGY AND GENETICS IN CLINICAL/TRANSLATIONAL RESEARCH

Background

Contact

full name

  • Stephen M. Kaminsky

primary email

  • smkamins@med.cornell.edu

External Relationships

externalRelationships

  • Relationships and collaborations with for-profit and not-for-profit organizations are of vital importance to our faculty because these exchanges of scientific information foster innovation. As experts in their fields, WCM physicians and scientists are sought after by many organizations to consult and educate. WCM and its faculty make this information available to the public, thus creating a transparent environment.

    Other Interests refers to miscellaneous financial interests not covered in other categories (e.g., stipends, anything of monetary value)Other Interest:
    Agathos Biologics; Nanoscope Therapeutics, Inc
    Ownership refers to any financial stake an individual owns in any company (e.g., stock options, equity interest)Ownership:
    Agathos Biologics; LEXEO Therapeutics, Inc.
    Proprietary Interest refers to ownership of intellectual property rights (e.g., trademarks, patents, royalty income)Proprietary Interest:
    LEXEO Therapeutics, Inc.